Literature DB >> 20137664

[Value of degree diagnosis with color Doppler flow imaging in the treatment of male erectile dysfunction].

Xu-jun Xuan1, Peng Sun, Jian-bo Teng, Hai-nan Liu, Hua Mei.   

Abstract

OBJECTIVE: To study the value of degree diagnosis with color Doppler flow imaging (CDFI) in the treatment of male erectile dysfunction (ED).
METHODS: After CDFI and intracavernosal vasoactive agent injection (ICI) with papaverine 60 mg and prostaglandin E(1) 10 microg, 198 male ED patients were divided into 4 groups by their penile stiffness based on the Schramek criterion. The therapeutic methods such as antibiotics for prostatitis, sexual behavior therapy, sildenafil, vacuum constriction device (VCD), vena fistula repairing operation, prosthetic implantation and enhanced external counterpulsation (EECP) were recommended to the patients according to their different penile stiffness degree and their different preferences.
RESULTS: Prior to ICI, there was no significant difference in the cavernosa artery peak systolic velocities (PSV), end diastolic velocities (EDV), resistant indexes (RI), dorsal artery PSV, EDV, RI and deep dorsal vein velocity (V) (P > 0.05). After ICI, the cavernosa artery PSV, EDV and RI were significantly different (P < 0.05) while other indices were not (P > 0.05). The patients were treated differently according to their preferences. The selective goal-oriented therapy increased the satisfactory rate to 91.91% (182/198).
CONCLUSION: Based on the penile stiffness degree with CDFI plus ICI, different therapeutic methods yield a better clinical outcome.

Entities:  

Mesh:

Year:  2009        PMID: 20137664

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  1 in total

1.  The application of color Doppler flow imaging in the diagnosis and therapeutic effect evaluation of erectile dysfunction.

Authors:  Xu-Jun Xuan; Gang Bai; Cai-Xia Zhang; Chao Xu; Fu-Ding Lu; Yang Peng; Gang Ma; Cong-Hui Han; Jun Chen
Journal:  Asian J Androl       Date:  2016 Jan-Feb       Impact factor: 3.285

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.